Intuitive Surgical Inc. ISRG

Intuitive Surgical, Inc. desarrolla, fabrica y comercializa el sistema quirúrgico da Vinci y el sistema endoluminal Ion. Los productos da Vinci de la compañía se ofrecen en categorías que incluyen Sistemas Quirúrgicos da Vinci, instrumentos y accesorios da Vinci, grapadoras da Vinci, energía da Vinci y visión da Vinci, que incluye sistemas de imagen de fluorescencia Firefly (Firefly) y endoscopios da Vinci. También proporciona una amplia gama de servicios, programas de formación y educación. Fabrica un conjunto de instrumentos que incorpora la tecnología EndoWrist con articulaciones articuladas para una destreza natural y puntas personalizadas para diversos procedimientos quirúrgicos. Su sistema endoluminal Ion es una plataforma robótica asistida por catéter diseñada para navegar a través de las vías respiratorias pulmonares muy pequeñas para llegar a nódulos periféricos para biopsias. El Sistema Quirúrgico da Vinci permite a los cirujanos operar mientras están sentados en una consola ergonómica viendo una imagen tridimensional de alta definición (3DHD) del campo quirúrgico.

ISRG hizo una división de acciones (split) de 3:1 el 5 de octubre de 2021: cada acción se convirtió en 3. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 2 oct

  Can ISRG Offset China Weakness With Expansion in India and Japan?

  Intuitive Surgical faces headwinds in China due to weak tenders, domestic competition, and pricing pressure, with only two systems placed. However, the company is diversifying growth through strong momentum in India following da Vinci 5 clearance and improved conditions in Japan with new reimbursement policies supporting 25 system placements. International da Vinci procedures grew 20% in Q2, with management maintaining its 2026 procedure growth outlook of 13.5-15.5%.

  

• Zacks Investment Research 30 sept

  10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

  10x Genomics has begun commercial shipments of Atera, its next-generation spatial biology platform, with booked orders exceeding 40 instruments and demand surpassing initial 2026 expectations. The platform enables whole-transcriptome analysis with single-cell sensitivity and is gaining traction across academic, translational, and biopharma research. The global spatial transcriptomics market is projected to reach $495.2 million by 2026 with a 14.7% CAGR through 2033.

  

• Zacks Investment Research 29 sept

  Top Stock Reports for Visa, Intuitive Surgical & Williams Companies

  Zacks analysts published research on 16 major stocks on September 29, 2026. Visa maintains strong market position in digital payments but faces margin pressure from rising client incentives. Intuitive Surgical underperforms due to moderated U.S. procedure growth and China headwinds, though the platform remains solid. Williams Companies shows healthy momentum with raised guidance but carries high debt and valuation concerns. Additional coverage includes analysis of Friedman Industries, Jones Soda, Hershey, W.P. Carey, and other companies across various sectors.

  

• Zacks Investment Research 29 sept

  Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

  McKesson raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00 following strong Q1 results with 20% EPS growth. The company is benefiting from robust growth in oncology services, specialty distribution, and GLP-1 therapies, which generated $15 billion in Q1 revenues. However, headwinds include branded drug price declines, generic conversion pressure, and regulatory uncertainty around 340B reform and IRA Part D changes.

  

• Zacks Investment Research 29 sept

  Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

  Revvity (RVTY) is rated a Hold with strong growth potential across diagnostics, life sciences, and scientific informatics. The company benefits from AI-driven demand, the planned Human Cell Design acquisition, and solid diagnostics growth (11% organic revenue increase in Q2). However, challenges include China divestiture uncertainty, uneven academic funding, and margin pressure from non-recurring tariff benefits. The stock has outperformed the broader market with a 56.1% year-to-date gain.